Möchten Sie immer auf dem neuesten Stand bleiben?

Transaction by Person Discharging Managerial Responsibilities Disclosure Rule DTR 3.1.4 On 3 January 2016, Pascal Soriot, a Director of the Company, notified us that, on 31 December 2015, he ceased...

Result of the External Audit Tender AstraZeneca PLC (the Company) today announced a proposal to appoint PricewaterhouseCoopers LLP (PwC) as its external auditor for the financial year ending 31...

ZURAMPIC® (LESINURAD) APPROVED BY US FDA FOR PATIENTS WITH GOUT AstraZeneca (http://www.astrazeneca-us.com/) today announced that the US Food and Drug Administration (FDA) has approved...

TAGRISSO™ (osimertinib) RECEIVES positive chmp OPINION FOR patients with EGFR T790M mutation-positive METASTATIC non-small cell lung cancer CHMP positive recommendation is based on an objective...

CHMP ISSUES POSITIVE OPINION ON LESINURAD FOR GOUT AstraZeneca today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a...

BRILIQUE (TICAGRELOR) RECEIVES POSITIVE EUROPEAN UNION CHMP OPINION FOR EXTENDED TREATMENT OF PATIENTS with a history of heart attack AstraZeneca today announced that the Committee for Medicinal...

DURVALUMAB atlantic TRIAL supports clinical activity and ASTRAZENECA'S OVERALL Immuno-Oncology Strategy Durvalumab demonstrated clinical activity and durable responses in 3rd-line or later stage...

AstraZeneca COMPLETES ACQUISITION OF ZS PHARMA AstraZeneca announced today the successful completion of the tender offer for all of the outstanding shares of ZS Pharma (NASDAQ: ZSPH) and the...

ASTRAZENECA ENHANCES LONG TERM GROWTH THROUGH ONCOLOGY INVESTMENT IN ACERTA PHARMA  Transaction includes late-stage, potential best-in-class irreversible small molecule BTK inhibitor,...

ASTRAZENECA TO STRENGTHEN THERAPY AREA FRANCHISE THROUGH ACQUISITION OF TAKEDA'S RESPIRATORY BUSINESS Acquisition to include non-US rights to roflumilast and will be accretive to 2016 earnings,...